Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Alphamab Oncology ( (HK:9966) ).
Alphamab Oncology has announced a significant financial turnaround, expecting to record a profit of at least RMB150.0 million for the year ended December 31, 2024, compared to a loss of approximately RMB210.6 million in 2023. This positive shift is attributed to three key license collaborations and increased sales revenue, marking the first time the company has achieved annual profits, which could potentially enhance its market position and stakeholder confidence.
More about Alphamab Oncology
Alphamab Oncology is a biotechnology company focused on the development and commercialization of innovative oncology therapies. It operates within the pharmaceutical industry, primarily dealing with cancer treatment products and services.
YTD Price Performance: 68.00%
Average Trading Volume: 3,982,325
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$5.67B
Find detailed analytics on 9966 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue